Textbook of Personalized Medicine - Second Edition [2015]

731

Transcription Activator-Like (TAL) Effector
Technology , 29–30
Translational science
defi nition , 32
methods of , 696–697
Trastuzumab (TCH) , 264, 295, 302
Traumatic brain injury , 415, 454
Traumatic injuries , 573–574
Trial assigning individualized options for
treatment (TAILORx) , 314
Triple negative breast cancer (TNBC) , 293,
304, 315–316
TrueMass ® , 173
Tuberculosis (TB) , 386–387
Tumor infi ltrating lymphocytes (TILs) , 247, 248
Tumor-initiating cells (TICs) , 278
Type 1 diabetes mellitus (T1DM) , 565–566
Type II diabetes mellitus (T2DM) , 565, 566
Tyrosine kinase inhibitors (TKIs)
EGFR , 347–350
PET imaging , 231

U
UGT1A1 test , 268–269
UK Modernizing Scientifi c Careers program ,
648–649
Unconjugated estriol (uE3) , 535
UNESCO’s Preservation of Parsi Zoroastrian
Project , 696
Unfolded protein response (UPR) , 307
United States (US), personalized medicine
academic institutions, role of
Baylor College of Medicine , 614–615
CPMC™ , 615–616
DVPMP , 616
Ignite Institute , 617–618
Indiana University , 618
Institute of Medicine , 619
IPIT , 627
Jackson Laboratory for Genomic
Medicine , 619
Johns Hopkins Kimmel Cancer
Center , 620
Massachusetts General Hospital , 623–624
Mayo Clinic , 620–621
Mount Sinai Medical Center , 621
NYGC , 622
OHSU , 624
P4 Medicine Institute , 622
PMP Florida , 623
Southeast Nebraska Cancer Center ,
624–625

Stanford Center for Genomics and

Personalized Medicine , 625

TCAG and DUMC , 616–617

UCHealth , 626–627

University of Alabama at

Birmingham , 626

Wisconsin Genomics Initiative , 627–628

AHRQ , 605–606

Centers for Disease Control , 614

Clinical Proteomics Program , 613

comparative effectiveness research , 605–608

DHHS , 604–605

EGAPP , 608–609

Genomics and Personalized Medicine Act ,

603–604

NHGRI , 611

NIGMS , 611–613

NIH ( see National Institute of Health (NIH))

NIST , 613

Obamacare/universal healthcare , 708

University of Alabama at Birmingham

(UAB) , 626

University of Colorado Health (UCHealth) ,

626–627

University of Connecticut (UConn) , 619

University of North Carolina (UNC) , 627

V

Valdecoxib , 557, 594

Vectra™ DA , 556

Velocity of diametric expansion (VDE) , 288

Venous leg ulcer (VLU) , 383–384

VeraTag™ assay system , 223

VereChip™ , 47

Verifi ® prenatal test , 540

Verpamil , 406

Viral infections

antiviral strategies , 387, 388

hepatitis B treatment , 401–402

hepatitis C treatment , 402–405

HIV ( see Human immunodefi ciency virus

(HIV))

ViroSeq ® HBV Assay , 402

ViroSeq ® HCV Assay , 405

ViroSeq HIV-1 Genotyping System , 396

Vitamin D receptor (VDR) gene , 581

Vynfi nit ® , 324

W

Warfarin , 120, 503, 504, 690

White blood cells (WBCs) , 79–80

Index